MZL Clinical Trial - A Study to Evaluate ICP-022 in Patients With R/R

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022. Safety, tolerability evaluation, and anti-tumor effects of ICP-022 in Chinese patients with R/R MZL will be evaluated in approximately 110 subjects. Pharmacokinetics of ICP-022 will be evaluated in approximately 20 subjects.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT03846427` - Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma	Phase 2
	Withdrawn	`NCT05176691` - HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL	Phase 1

NCT number	NCT03797456
Study type	Interventional
Source	Beijing InnoCare Pharma Tech Co., Ltd.
Contact
Status	Completed
Phase	Phase 2
Start date	April 1, 2019
Completion date	February 6, 2024

A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms